Free tool
Drug Trial Radar: Dermatology
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
6
Not yet recruiting, industry sponsors, Dermatology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed212
6 trials
Showing 1 to 6, recently updated first.
- Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual OnychomycosisPivotal-lookingNot yet recruiting
SATO Pharmaceutical Co., Ltd.Industry
NCT07929844 · 204 participants (planned) · Start Nov 24, 2026 · Primary completion Sep 23, 2028
Drug: SKX-16 (Luliconazole 10% Solution); Vehicle solution · For: Onychomycosis of Toenails
Sites: Los Angeles, California; San Francisco, California; Miami, Florida · 6 sites in all
- Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne VulgarisPivotal-lookingNot yet recruiting
AOBiome LLCIndustry
NCT07866105 · 176 participants (planned) · Start Oct 2026 · Primary completion Aug 2027
Drug: B244; Vehicle · For: Acne Vulgaris
- A Phase 2 Study of HW211026Not yet recruiting
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.Industry
NCT07513454 · 80 participants (planned) · Start Jul 2026 · Primary completion Dec 2026
Drug: HW211026; HW211026 · For: Actinic Keratosis
Sites: Shanghai, China
- A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.Not yet recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT07449156 · 21 participants (planned) · Start Mar 27, 2026 · Primary completion Oct 27, 2026
Drug: HB0043; Placebo · For: Acne Vulgaris
Sites: Jinan, China
- A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the ToenailsPivotal-lookingNot yet recruiting
Onyx AxiomAmgen (AMGN)
NCT07382427 · 200 participants (planned) · Start Mar 2026 · Primary completion Jan 2028
Drug: 2.4% Topical Terbinafine; 10% Topical Efinaconazole · For: Onychomycosis of Toenail
- Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne VulgarisPivotal-lookingNot yet recruiting
Jiangxi Kvvit Pharmaceutical Co., Ltd.Industry
NCT07345390 · 180 participants (planned) · Start Jan 10, 2026 · Primary completion Oct 30, 2026
Drug: KR230109 cream 0.025%; KR230109 cream 0.05% and 1 more · For: Acne Vulgaris
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.